IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL5.51▲ 0.05% USD/MXN18.44▼ 0.51% USD/CLP966.96▼ 0.99% USD/COP3,267▲ 4.70% USD/PEN3.41▼ 1.07% USD/ARS1,545▼ 0.02% USD/UYU40.45▲ 0.35% USD/PYG6,450▲ 1.45% USD/BOB11.74▼ 0.59% USD/DOP60.46▲ 2.41% USD/CRC446.56▼ 0.38% USD/GTQ7.64▼ 0.05% USD/HNL26.89▲ 0.02% USD/NIO36.62▲ 2.53% USD/VES897.02▲ 0.07% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.79▲ 2.42% USD/TTD6.72▼ 0.03% EUR/BRL6.19▲ 0.99% BRENT 90.82 ▼ 1.89% WTI 85.12 ▼ 1.99% IRON ORE 161.91 — — COPPER 6.32 ▼ 0.21% GOLD 4,124 ▲ 0.24% SILVER 52.79 ▲ 0.42% SOY 1,196 ▲ 1.12% CORN 441.50 ▲ 0.51% WHEAT 591.25 ▲ 0.55% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81% IBOV 172,236.05 ▲ 2.22% IPC MEX 71,866.30 ▲ 0.66% MERVAL 2,848,945 — — USD/BRL 5.51 ▲ 0.05% USD/MXN 18.45 ▼ 0.42% USD/CLP 966.96 ▼ 0.99% USD/COP 3,267 ▲ 4.70% USD/PEN 3.41 ▼ 1.07% USD/ARS 1,545 ▼ 0.02% USD/UYU 40.45 ▲ 0.35% USD/PYG 6,450 ▲ 1.45% USD/BOB 11.74 ▼ 0.59% USD/DOP 60.46 ▲ 2.41% USD/CRC 446.56 ▼ 0.38% USD/GTQ 7.64 ▼ 0.05% USD/HNL 26.89 ▲ 0.02% USD/NIO 36.62 ▲ 2.53% USD/VES 897.02 ▲ 0.07% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.79 ▲ 2.42% USD/TTD 6.72 ▲ 2.10% EUR/BRL 6.19 ▲ 0.99% BRENT 90.82 ▼ 1.89% WTI 85.12 ▼ 1.99% IRON ORE 161.91 — — COPPER 6.32 ▼ 0.21% GOLD 4,124 ▲ 0.24% SILVER 52.79 ▲ 0.42% SOY 1,196 ▲ 1.12% CORN 441.50 ▲ 0.51% WHEAT 591.25 ▲ 0.55% COFFEE 266.70 ▼ 4.75% SUGAR 18.21 ▼ 0.16% ORANGE JUICE 143.50 ▲ 7.85% COTTON 78.65 ▼ 0.58% COCOA 5,113 ▼ 0.81% BEEF 216.33 ▲ 1.06% CATTLE 324.80 ▲ 0.77% LITHIUM 61.35 ▲ 0.72% PETR4 45.19 ▼ 0.24% VALE3 66.11 ▲ 3.23% ITUB4 41.72 ▲ 2.94% BBDC4 14.68 ▲ 3.38% ABEV3 15.61 ▲ 0.84% BBAS3 17.02 ▼ 0.64% B3SA3 14.85 ▲ 3.20% WEGE3 50.74 ▲ 5.29% PRIO3 59.39 ▼ 1.80% SUZB3 54.20 ▲ 1.50% RENT3 30.83 ▲ 1.78% AZZA3 15.12 ▲ 2.44% CSAN3 2.77 — 0.00% RAIZ4 24.40 ▼ 12.86% PCAR3 2.43 ▲ 1.25% GMAT3 3.83 ▲ 0.79% PSSA3 45.65 ▲ 2.93% CVCB3 0.87 ▲ 3.57% POSI3 3.03 ▼ 1.94% SLCE3 17.30 ▲ 4.15% NATU3 5.71 ▲ 10.44% BRKM5 3.02 ▼ 5.63% RANI3 8.76 ▲ 3.44% CSNA3 4.49 ▲ 1.81%
since 2009
Tuesday, November 10, 2026

Covid-19 Brazil

Emergency use – Brazil’s Health Regulator suspends Sputnik V analysis deadline

By · · 2 min read

RIO DE JANEIRO, BRAZIL – The Brazilian Health Regulatory Agency (Anvisa) released a note this Saturday (March 27), advising the suspension of the deadlines for analysis of the request for emergency use of the Russian vaccine Sputnik V, made last week by União Química, the company responsible for the Russian immunization product, in Brazil.

“Due to the absence of documents considered important for the analysis, as provided by law, the deadlines were suspended until the company presents the information described as ‘not presented’ in the disclosed panel,” says the agency.

2
Anvisa adopted the measure due to the absence of documents.
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

According to Anvisa, the panel presents the percentage regarding the submission status of each of the reports and information necessary for the analysis of temporary and emergency use authorization.

Despite the deadline’s suspension, the Agency said it is continuing the analysis of the other information submitted by União Química.

Versamune

About Versamune, a vaccine developed in partnership with the University of São Paulo (USP), the company Farmacore and PDS Biotechnology, from the United States, Anvisa said it issued demands for more information to the USP Medical School of Ribeirão Preto, after analyzing the request to conduct clinical studies of phases 1 and 2 of the immunization development.

According to the Agency, the documentation was filed on Thursday (March 25) and that “the requirements do not suspend the analysis of the other information presented by the vaccine developers”.

Source: Agência Brasil

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.